Clinical Trial Update: A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase II trial evaluating carboplatin, Abraxane (paclitaxel protein-bound particles), and sorafenib in metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• CARBOPLATIN (Carboplatin)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Mt. Sinai Medical Center, Miami | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED